Written questions by Fortune.

Innovation and Technology, what the total amount of Government investment into acoustic neuroma research was in 2023-24; and which public bodies provided that investment.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.

Innovation and Technology, what the total amount of Government investment into meniere’s disease research was in 2023-24; and which public bodies provided that investment.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.

Innovation and Technology, what the total amount of Government investment into labyrithitis research was in 2023-24; and which public bodies provided that investment.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.

Innovation and Technology, what the total amount of Government investment into congenital deafness research was in 2023-24; and which public bodies provided that investment.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.

Innovation and Technology, what the total amount of Government investment into age related hearing loss research was in 2023-24; and which public bodies provided that investment.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.

Innovation and Technology, what the total amount of Government investment into otosclerosis research was in 2023-24; and which public bodies provided that investment.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.

Innovation and Technology, what the total amount of Government investment into tinnitus research was in 2023-24; and which public bodies provided that investment.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.

Innovation and Technology, what the total amount of Government investment into neurofibromatosis research was in 2023-24; and which public bodies provided that investment.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.

Innovation and Technology, what the total amount of Government investment into cholesteatoma research was in 2023-24; and which public bodies provided that investment.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.

Innovation and Technology, what the total amount of Government investment into otitis externa research was in 2023-24; and which public bodies provided that investment.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.

Innovation and Technology, what the total amount of Government investment into otitis media with effusion research was in 2023-24; and which public bodies provided that investment.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.

Innovation and Technology, what the total amount of Government investment into noise induced hearing loss research was in 2023-24; and which public bodies provided that investment.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.

Innovation and Technology, how much funding the Government provided for research into alcoholic fatty liver disease in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases. Details of UKRI and NIHR funding on specific areas is provided in the table below: UIN NIHR funding in FY 2023/24UKRI Funding in FY 2023/2428175Hepatitis BNIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24.The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC.28176Hepatitis C UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24.28177Hepatocellular carcinomaNIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24.The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes).28178CholangiocarcinomaNIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award.28179Biliary cirrhosisNIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24.28180Sclerosing cholangitisNIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24.28181Autoimmune hepatitisNIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24UKRI did not commit any funding for autoimmune hepatitis research in 2023-24.28182Non-alcoholic fatty liver diseaseNIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24.The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes).28183Alcoholic fatty liver diseaseUKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into primary biliary cirrhosis in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases. Details of UKRI and NIHR funding on specific areas is provided in the table below: UIN NIHR funding in FY 2023/24UKRI Funding in FY 2023/2428175Hepatitis BNIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24.The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC.28176Hepatitis C UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24.28177Hepatocellular carcinomaNIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24.The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes).28178CholangiocarcinomaNIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award.28179Biliary cirrhosisNIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24.28180Sclerosing cholangitisNIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24.28181Autoimmune hepatitisNIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24UKRI did not commit any funding for autoimmune hepatitis research in 2023-24.28182Non-alcoholic fatty liver diseaseNIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24.The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes).28183Alcoholic fatty liver diseaseUKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into cholangiocarcinoma in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases. Details of UKRI and NIHR funding on specific areas is provided in the table below: UIN NIHR funding in FY 2023/24UKRI Funding in FY 2023/2428175Hepatitis BNIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24.The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC.28176Hepatitis C UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24.28177Hepatocellular carcinomaNIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24.The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes).28178CholangiocarcinomaNIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award.28179Biliary cirrhosisNIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24.28180Sclerosing cholangitisNIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24.28181Autoimmune hepatitisNIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24UKRI did not commit any funding for autoimmune hepatitis research in 2023-24.28182Non-alcoholic fatty liver diseaseNIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24.The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes).28183Alcoholic fatty liver diseaseUKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into Hepatitis B in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases. Details of UKRI and NIHR funding on specific areas is provided in the table below: UIN NIHR funding in FY 2023/24UKRI Funding in FY 2023/2428175Hepatitis BNIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24.The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC.28176Hepatitis C UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24.28177Hepatocellular carcinomaNIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24.The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes).28178CholangiocarcinomaNIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award.28179Biliary cirrhosisNIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24.28180Sclerosing cholangitisNIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24.28181Autoimmune hepatitisNIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24UKRI did not commit any funding for autoimmune hepatitis research in 2023-24.28182Non-alcoholic fatty liver diseaseNIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24.The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes).28183Alcoholic fatty liver diseaseUKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into hepatocellular carcinoma in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases. Details of UKRI and NIHR funding on specific areas is provided in the table below: UIN NIHR funding in FY 2023/24UKRI Funding in FY 2023/2428175Hepatitis BNIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24.The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC.28176Hepatitis C UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24.28177Hepatocellular carcinomaNIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24.The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes).28178CholangiocarcinomaNIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award.28179Biliary cirrhosisNIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24.28180Sclerosing cholangitisNIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24.28181Autoimmune hepatitisNIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24UKRI did not commit any funding for autoimmune hepatitis research in 2023-24.28182Non-alcoholic fatty liver diseaseNIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24.The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes).28183Alcoholic fatty liver diseaseUKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into non-alcoholic fatty liver disease in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases. Details of UKRI and NIHR funding on specific areas is provided in the table below: UIN NIHR funding in FY 2023/24UKRI Funding in FY 2023/2428175Hepatitis BNIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24.The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC.28176Hepatitis C UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24.28177Hepatocellular carcinomaNIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24.The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes).28178CholangiocarcinomaNIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award.28179Biliary cirrhosisNIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24.28180Sclerosing cholangitisNIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24.28181Autoimmune hepatitisNIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24UKRI did not commit any funding for autoimmune hepatitis research in 2023-24.28182Non-alcoholic fatty liver diseaseNIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24.The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes).28183Alcoholic fatty liver diseaseUKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into autoimmune hepatitis in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases. Details of UKRI and NIHR funding on specific areas is provided in the table below: UIN NIHR funding in FY 2023/24UKRI Funding in FY 2023/2428175Hepatitis BNIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24.The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC.28176Hepatitis C UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24.28177Hepatocellular carcinomaNIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24.The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes).28178CholangiocarcinomaNIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award.28179Biliary cirrhosisNIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24.28180Sclerosing cholangitisNIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24.28181Autoimmune hepatitisNIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24UKRI did not commit any funding for autoimmune hepatitis research in 2023-24.28182Non-alcoholic fatty liver diseaseNIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24.The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes).28183Alcoholic fatty liver diseaseUKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into primary sclerosing cholangitis in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases. Details of UKRI and NIHR funding on specific areas is provided in the table below: UIN NIHR funding in FY 2023/24UKRI Funding in FY 2023/2428175Hepatitis BNIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24.The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC.28176Hepatitis C UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24.28177Hepatocellular carcinomaNIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24.The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes).28178CholangiocarcinomaNIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award.28179Biliary cirrhosisNIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24.28180Sclerosing cholangitisNIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24.28181Autoimmune hepatitisNIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24UKRI did not commit any funding for autoimmune hepatitis research in 2023-24.28182Non-alcoholic fatty liver diseaseNIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24.The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes).28183Alcoholic fatty liver diseaseUKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24.